May 1 |
TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
|
May 1 |
TG Therapeutics GAAP EPS of -$0.07 misses by $0.03, revenue of $63.47M beats by $8.86M
|
May 1 |
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
|
Apr 30 |
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
|
Apr 30 |
After Plunging -9.82% in 4 Weeks, Here's Why the Trend Might Reverse for TG Therapeutics (TGTX)
|
Apr 18 |
TG Therapeutics wins VA contract for Briumvi
|
Apr 18 |
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|
Apr 18 |
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
|
Apr 17 |
TG Therapeutics: The Cloud Over Briumvi
|
Apr 15 |
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
|